Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 3/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 5/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208424 | 0.91 | CYP2A6 (0.50) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL865990 | 0.77 | CYP2A6 (0.77) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL29644361 | 0.77 | CYP2A6 (0.77) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL129202 | 0.77 | — | — | |
| SCHEMBL11787164 | 0.75 | CYP2A6 (0.44) | CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL70257 | 0.75 | — | — | |
| SCHEMBL559813 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL29200223 | 0.74 | CYP2A6 (0.72) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL8590694 | 0.74 | CYP2A6 (0.46) | CYP2A6F11AHR | |
| SCHEMBL50089 | 0.73 | CYP1A2 (0.50) | TSHRCYP3A4TDP1ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| WO-2024037422-A1 | CRYSTALLINE FORMS OF A GLUCOSYLCERAMIDE SYNTHASE INHIBITOR AND USES THEREOF | ACELINK THERAPEUTICS (SUZHOU) CO., LTD (CN) | 2024-02-22 | — | — | WO | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | claimed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| EP-0108488-B1 | (1-ARYLCYCLOBUTYL) (HETEROCYCLYL) METHYLAMINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1986-02-26 | — | — | EP | claimed |
| US-4474791-A | Diuretic 2,6-diaryl-4-pyridine carboxylic acids | THE UPJOHN COMPANY (US) | 1984-10-02 | — | — | US | claimed |
| EP-0064385-A1 | 2,6-Diaryl-pyridinecarboxylic acids and their therapeutic utility | THE UPJOHN COMPANY (US) | 1982-11-10 | — | — | EP | claimed |
| US-4104392-A | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1978-08-01 | — | — | US | claimed |
| US-4096255-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-20 | — | — | US | claimed |
| US-4073916-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4073914-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4072744-A | SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-07 | — | — | US | claimed |
| US-4070457-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-24 | — | — | US | claimed |
| US-4036955-A | TREATMENT OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-07-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | CYP2A6 756/4885F11 1880/4885AHR 998/4885 |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | CYP2A6 2603/4885F11 4663/4885AHR 189/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 788/4885F11 1965/4885AHR 1048/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 788/4885F11 1965/4885AHR 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.